Racial Inequalities in Liver Cancer Deaths Soared After Launch of Hepatitis C Drugs

A study explored racial inequalities in death from liver cancer before and after the introduction of lifesaving drugs for hepatitis C. Results showed that from 1979 to 1998, racial inequalities in mortality from liver cancer in the U.S. were declining. But, from 1998 to 2016, of the 16,770 deaths from liver cancer among blacks, the excess relative to whites increased from 27.8 percent to 45.4 percent. Concurrently, racial inequalities in death decreased for major risk factors for liver cancer, such as alcohol and diabetes.

Read more

House Drug Pricing Bill Serves Patients, Public Health

H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act passed by the House of Representatives today introduces critically needed and significant steps to reduce costs and improve access to life-saving therapies for conditions including HIV and hepatitis C. Importantly, the legislation also brings essential resources to combat antibiotic resistance, find and develop new infection fighting drugs and bring them to market. The balanced approach of this legislation will serve patients and public health.

Read more

HCV Guidance Updates Recommendations for Identification and Management of Chronic Hep C

HCVguidelines.org — a website developed by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America to provide up-to-date guidance on the management of hepatitis C — was recently revised to reflect important developments in the identification and management of chronic hepatitis C (HCV)

Read more

All-Oral Direct-Acting Antiviral Treatments Improve Survival in Patients with HCV-Related Hepatocellular Carcinoma

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that hepatitis C virus-related hepatocellular carcinoma (HCC) patients who achieved sustained virologic response (SVR) – denoting an undetectable level of HCV virus – with any oral direct-acting antiviral (DAA) had over 60-70 percent improvement in five-year survival.

Read more